Inactivating PTH/PTHrP Signaling Disorders

Giovanna Mantovani, Francesca M. Elli

Research output: Contribution to journalArticle

Abstract

Pseudohypoparathyroidism (PHP), pseudo-PHP, acrodysostosis, and progressive osseous heteroplasia are heterogeneous disorders characterized by physical findings, differently associated in each subtype, including short bones, short stature, a stocky build, ectopic ossifications (features associated with Albright's hereditary osteodystrophy), as well as laboratory abnormalities consistent with hormone resistance, such as hypocalcemia, hyperphosphatemia, and elevated parathyroid hormone (PTH) and thyroid-stimulating hormone levels. All these disorders are caused by impairments in the cAMP-mediated signal transduction pathway and, in particular, in the PTH/PTHrP signaling pathway: The main subtypes of PHP and related disorders are caused by de novo or autosomal dominantly inherited inactivating genetic mutations, and/or epigenetic, sporadic, or genetic-based alterations within or upstream of GNAS, PRKAR1A, PDE4D, and PDE3A. Here we will review the impressive progress that has been made over the past 30 years on the pathophysiology of these diseases and will describe the recently proposed novel nomenclature and classification. The new term "inactivating PTH/PTHrP signaling disorder," iPPSD: (1) defines the common mechanism responsible for all diseases, (2) does not require a confirmed genetic defect, (3) avoids ambiguous terms like "pseudo," and (4) eliminates the clinical or molecular overlap between diseases.

Original languageEnglish
Pages (from-to)147-159
Number of pages13
JournalFrontiers of Hormone Research
Volume51
DOIs
Publication statusPublished - 2019

Fingerprint

Parathyroid Hormone-Related Protein
Parathyroid Hormone
Pseudohypoparathyroidism
Pseudopseudohypoparathyroidism
Hyperphosphatemia
Heterotopic Ossification
Hypocalcemia
Thyrotropin
Terminology
Epigenomics
Signal Transduction
Hormones
Bone and Bones
Mutation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Inactivating PTH/PTHrP Signaling Disorders. / Mantovani, Giovanna; Elli, Francesca M.

In: Frontiers of Hormone Research, Vol. 51, 2019, p. 147-159.

Research output: Contribution to journalArticle

Mantovani, Giovanna ; Elli, Francesca M. / Inactivating PTH/PTHrP Signaling Disorders. In: Frontiers of Hormone Research. 2019 ; Vol. 51. pp. 147-159.
@article{55331d57c56745cf81266c0e919824f8,
title = "Inactivating PTH/PTHrP Signaling Disorders",
abstract = "Pseudohypoparathyroidism (PHP), pseudo-PHP, acrodysostosis, and progressive osseous heteroplasia are heterogeneous disorders characterized by physical findings, differently associated in each subtype, including short bones, short stature, a stocky build, ectopic ossifications (features associated with Albright's hereditary osteodystrophy), as well as laboratory abnormalities consistent with hormone resistance, such as hypocalcemia, hyperphosphatemia, and elevated parathyroid hormone (PTH) and thyroid-stimulating hormone levels. All these disorders are caused by impairments in the cAMP-mediated signal transduction pathway and, in particular, in the PTH/PTHrP signaling pathway: The main subtypes of PHP and related disorders are caused by de novo or autosomal dominantly inherited inactivating genetic mutations, and/or epigenetic, sporadic, or genetic-based alterations within or upstream of GNAS, PRKAR1A, PDE4D, and PDE3A. Here we will review the impressive progress that has been made over the past 30 years on the pathophysiology of these diseases and will describe the recently proposed novel nomenclature and classification. The new term {"}inactivating PTH/PTHrP signaling disorder,{"} iPPSD: (1) defines the common mechanism responsible for all diseases, (2) does not require a confirmed genetic defect, (3) avoids ambiguous terms like {"}pseudo,{"} and (4) eliminates the clinical or molecular overlap between diseases.",
author = "Giovanna Mantovani and Elli, {Francesca M.}",
year = "2019",
doi = "10.1159/000491045",
language = "English",
volume = "51",
pages = "147--159",
journal = "Frontiers of Hormone Research",
issn = "0301-3073",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Inactivating PTH/PTHrP Signaling Disorders

AU - Mantovani, Giovanna

AU - Elli, Francesca M.

PY - 2019

Y1 - 2019

N2 - Pseudohypoparathyroidism (PHP), pseudo-PHP, acrodysostosis, and progressive osseous heteroplasia are heterogeneous disorders characterized by physical findings, differently associated in each subtype, including short bones, short stature, a stocky build, ectopic ossifications (features associated with Albright's hereditary osteodystrophy), as well as laboratory abnormalities consistent with hormone resistance, such as hypocalcemia, hyperphosphatemia, and elevated parathyroid hormone (PTH) and thyroid-stimulating hormone levels. All these disorders are caused by impairments in the cAMP-mediated signal transduction pathway and, in particular, in the PTH/PTHrP signaling pathway: The main subtypes of PHP and related disorders are caused by de novo or autosomal dominantly inherited inactivating genetic mutations, and/or epigenetic, sporadic, or genetic-based alterations within or upstream of GNAS, PRKAR1A, PDE4D, and PDE3A. Here we will review the impressive progress that has been made over the past 30 years on the pathophysiology of these diseases and will describe the recently proposed novel nomenclature and classification. The new term "inactivating PTH/PTHrP signaling disorder," iPPSD: (1) defines the common mechanism responsible for all diseases, (2) does not require a confirmed genetic defect, (3) avoids ambiguous terms like "pseudo," and (4) eliminates the clinical or molecular overlap between diseases.

AB - Pseudohypoparathyroidism (PHP), pseudo-PHP, acrodysostosis, and progressive osseous heteroplasia are heterogeneous disorders characterized by physical findings, differently associated in each subtype, including short bones, short stature, a stocky build, ectopic ossifications (features associated with Albright's hereditary osteodystrophy), as well as laboratory abnormalities consistent with hormone resistance, such as hypocalcemia, hyperphosphatemia, and elevated parathyroid hormone (PTH) and thyroid-stimulating hormone levels. All these disorders are caused by impairments in the cAMP-mediated signal transduction pathway and, in particular, in the PTH/PTHrP signaling pathway: The main subtypes of PHP and related disorders are caused by de novo or autosomal dominantly inherited inactivating genetic mutations, and/or epigenetic, sporadic, or genetic-based alterations within or upstream of GNAS, PRKAR1A, PDE4D, and PDE3A. Here we will review the impressive progress that has been made over the past 30 years on the pathophysiology of these diseases and will describe the recently proposed novel nomenclature and classification. The new term "inactivating PTH/PTHrP signaling disorder," iPPSD: (1) defines the common mechanism responsible for all diseases, (2) does not require a confirmed genetic defect, (3) avoids ambiguous terms like "pseudo," and (4) eliminates the clinical or molecular overlap between diseases.

UR - http://www.scopus.com/inward/record.url?scp=85057320847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057320847&partnerID=8YFLogxK

U2 - 10.1159/000491045

DO - 10.1159/000491045

M3 - Article

VL - 51

SP - 147

EP - 159

JO - Frontiers of Hormone Research

JF - Frontiers of Hormone Research

SN - 0301-3073

ER -